- Home
- BPTH vs PRSO Comparison
BPTH vs PRSO Comparison
Compare BPTH & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- PRSO
- Stock Information
- Founded
- BPTH 2007
- PRSO 2008
- Country
- BPTH United States
- PRSO United States
- Employees
- BPTH N/A
- PRSO N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- PRSO Semiconductors
- Sector
- BPTH Health Care
- PRSO Technology
- Exchange
- BPTH Nasdaq
- PRSO Nasdaq
- Market Cap
- BPTH 4.8M
- PRSO 4.0M
- IPO Year
- BPTH N/A
- PRSO 2001
- Fundamental
- Price
- BPTH $0.73
- PRSO $0.90
- Analyst Decision
- BPTH Strong Buy
- PRSO Strong Buy
- Analyst Count
- BPTH 2
- PRSO 2
- Target Price
- BPTH $30.00
- PRSO $3.38
- AVG Volume (30 Days)
- BPTH 161.7K
- PRSO 191.2K
- Earning Date
- BPTH 03-07-2025
- PRSO 03-17-2025
- Dividend Yield
- BPTH N/A
- PRSO N/A
- EPS Growth
- BPTH N/A
- PRSO N/A
- EPS
- BPTH N/A
- PRSO N/A
- Revenue
- BPTH N/A
- PRSO $12,728,000.00
- Revenue This Year
- BPTH N/A
- PRSO $9.59
- Revenue Next Year
- BPTH N/A
- PRSO $1.63
- P/E Ratio
- BPTH N/A
- PRSO N/A
- Revenue Growth
- BPTH N/A
- PRSO N/A
- 52 Week Low
- BPTH $0.59
- PRSO $0.73
- 52 Week High
- BPTH $10.00
- PRSO $2.34
- Technical
- Relative Strength Index (RSI)
- BPTH 37.30
- PRSO 41.46
- Support Level
- BPTH $0.78
- PRSO $0.82
- Resistance Level
- BPTH $0.84
- PRSO $0.92
- Average True Range (ATR)
- BPTH 0.05
- PRSO 0.10
- MACD
- BPTH -0.02
- PRSO -0.02
- Stochastic Oscillator
- BPTH 4.05
- PRSO 10.81
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.